BioAtla, Inc. (NASDAQ:BCAB) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET

Company Participants

Bruce Mackle - Investor Relations

Jay Short - Chairman, Chief Executive Officer and Co-Founder

Scott Smith - President

Philippe Martin - Chief, Clinical Development and Operations

Sheri Lydick - Senior Vice President, Commercial Strategy

Richard Waldron - Chief Financial Officer

Conference Call Participants

Brian Cheng - JPMorgan

Kelly Shi - Jefferies

Tony Butler - ROTH Capital

Arthur He - H.C. Wainwright

Reni Benjamin - JMP Securities

Operator

Good day and welcome to the BioAtla Third Quarter 2022 Earnings Conference Call – pardon me, BioAtla. [Operator Instructions] I would now like to turn the conference over to Bruce Mackle from LifeSci Advisors. Please go ahead.

Bruce Mackle

Thank you, operator and good afternoon everyone. With me today on the phone from BioAtla are Dr. Jay Short, Chairman, CEO and Co-Founder; Scott Smith, President; Philippe Martin, Chief of Clinical Development and Operations; Sheri Lydick, Senior Vice President, Commercial Strategy; and Richard Waldron, Chief Financial Officer. Earlier this afternoon, BioAtla released financial results and a business update for the quarter ended September 30, 2022. A copy of the press release is available on the company’s website.

Before we begin, I’d like to remind everyone that statements made during this conference call will include forward-looking statements, including, but not limited to, statements regarding BioAtla’s business plans and prospects, potential selective licensing collaborations and other strategic partnerships, whether our clinical trials will be potentially registrational, results, conduct, progress and timing of our research and development programs and clinical trials; expectations with respect to enrollment and dosing in our clinical trials, plans regarding future data updates, clinical trials, regulatory meetings and regulatory submissions, the potential regulatory approval path for our product candidates; expectations about the sufficiency of our cash and cash equivalents and expected R&D and G&A expenses. These statements are subject to various risks, assumptions and uncertainties that can cause actual results to differ materially and are described in the filings made with the SEC, including the most recent quarterly report on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today, November 3, 2022, and BioAtla disclaims any obligation to update such statements to reflect future information, events or circumstances, except as required by law.

With that, I’d like to turn the call over to Jay Short. Jay?